Cytek Biosciences, Inc. (NASDAQ:CTKB) Holdings Raised by Allspring Global Investments Holdings LLC
Cytek Biosciences, Inc. (NASDAQ:CTKB) Holdings Raised by Allspring Global Investments Holdings LLC
Allspring Global Investments Holdings LLC grew its stake in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB – Get Rating) by 54.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,077 shares of the company's stock after purchasing an additional 1,789 shares during the period. Allspring Global Investments Holdings LLC's holdings in Cytek Biosciences were worth $74,000 as of its most recent SEC filing.
根据最近提交给美国证券交易委员会的Form 13F文件，AllSpring Global Investments Holdings LLC在第三季度增持了Cytek Biosciences，Inc.(纳斯达克代码：CTKB-GET Rating)的股份，增幅为54.4%。该基金持有该公司5,077股股票，在此期间又购买了1,789股。截至最近提交给美国证券交易委员会的文件，AllSpring Global Investments Holdings LLC持有的赛特克生物科学公司股份价值74,000美元。
Several other hedge funds have also modified their holdings of CTKB. Principal Financial Group Inc. purchased a new stake in Cytek Biosciences in the 1st quarter worth about $171,000. ProShare Advisors LLC purchased a new stake in Cytek Biosciences in the 1st quarter worth about $197,000. JPMorgan Chase & Co. lifted its stake in Cytek Biosciences by 402.5% in the 1st quarter. JPMorgan Chase & Co. now owns 49,906 shares of the company's stock worth $538,000 after acquiring an additional 39,974 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Cytek Biosciences by 403.9% in the 1st quarter. Bank of New York Mellon Corp now owns 266,335 shares of the company's stock worth $2,871,000 after acquiring an additional 213,476 shares in the last quarter. Finally, MetLife Investment Management LLC lifted its stake in Cytek Biosciences by 749.0% in the 1st quarter. MetLife Investment Management LLC now owns 54,754 shares of the company's stock worth $590,000 after acquiring an additional 48,305 shares in the last quarter. 49.48% of the stock is owned by hedge funds and other institutional investors.
其他几家对冲基金也调整了对CTKB的持股。信安金融集团在第一季度购买了Cytek Biosciences价值约17.1万美元的新股份。ProShare Advisors LLC在第一季度购买了Cytek Biosciences的新股份，价值约19.7万美元。今年第一季度，摩根大通将其在赛特克生物科技的持股比例提高了402.5%。摩根大通在上个季度增持了39,974股后，目前持有49,906股该公司股票，价值538,000美元。纽约梅隆银行(Bank Of New York Mellon Corp)在第一季度增持了赛特克生物科学公司的股份，增幅为403.9%。纽约梅隆银行(Bank Of New York Mellon Corp)目前持有266,335股该公司股票，价值2,871,000美元，此前该公司在上一季度增持了213,476股。最后，大都会人寿投资管理有限责任公司在第一季度将其在赛特克生物科学公司的持股比例提高了749.0%。大都会人寿投资管理有限责任公司现在拥有54,754股该公司股票，价值59万美元，上个季度又收购了48,305股。49.48%的股票由对冲基金和其他机构投资者持有。
Analysts Set New Price Targets
分析师设定新的价格目标
Separately, Piper Sandler increased their price objective on Cytek Biosciences from $16.00 to $18.00 in a research note on Monday, November 14th.
另外，派珀·桑德勒在11月14日星期一的一份研究报告中将Cytek Biosciences的目标价从16.00美元上调至18.00美元。
Cytek Biosciences Price Performance
Cytek Bioscions性价比
Cytek Biosciences (NASDAQ:CTKB – Get Rating) last posted its quarterly earnings results on Wednesday, November 9th. The company reported $0.01 earnings per share for the quarter, missing analysts' consensus estimates of $0.02 by ($0.01). Cytek Biosciences had a positive return on equity of 0.94% and a negative net margin of 0.47%. The firm had revenue of $40.48 million for the quarter, compared to analysts' expectations of $43.36 million. On average, equities research analysts expect that Cytek Biosciences, Inc. will post 0.04 earnings per share for the current fiscal year.
赛特克生物科学公司(纳斯达克代码：CTKB-GET Rating)最近一次公布季度收益报告是在11月9日星期三。该公司公布本季度每股收益为0.01美元，低于分析师普遍预期的0.02美元(合0.01美元)。Cytek Biosciences的股本回报率为正0.94%，净利润率为负0.47%。该公司当季营收为4,048万美元，高于分析师预期的4,336万美元。股票研究分析师平均预计，Cytek Biosciences，Inc.本财年每股收益将为0.04美元。
Insider Transactions at Cytek Biosciences
赛特克生物科学公司的内幕交易
In other news, CEO Wenbin Jiang sold 20,000 shares of the stock in a transaction dated Monday, November 7th. The stock was sold at an average price of $14.76, for a total transaction of $295,200.00. Following the transaction, the chief executive officer now owns 7,785,820 shares of the company's stock, valued at approximately $114,918,703.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CEO Wenbin Jiang sold 20,000 shares of the stock in a transaction dated Monday, November 7th. The stock was sold at an average price of $14.76, for a total transaction of $295,200.00. Following the transaction, the chief executive officer now owns 7,785,820 shares of the company's stock, valued at approximately $114,918,703.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Jack Ball sold 16,000 shares of the stock in a transaction dated Monday, November 14th. The shares were sold at an average price of $14.69, for a total value of $235,040.00. Following the transaction, the director now directly owns 3,000 shares in the company, valued at approximately $44,070. The disclosure for this sale can be found here. Insiders sold 146,500 shares of company stock valued at $1,824,960 in the last three months. Corporate insiders own 15.90% of the company's stock.
在其他新闻方面，首席执行官蒋文斌在11月7日星期一的一笔交易中出售了2万股该股。该股以14.76美元的平均价格出售，总成交金额为295,200.00美元。交易完成后，这位首席执行官现在拥有该公司7,785,820股股票，价值约114,918,703.20美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可通过此超链接。在其他新闻方面，首席执行官蒋文斌在11月7日星期一的一笔交易中出售了2万股该股。该股以14.76美元的平均价格出售，总成交金额为295,200.00美元。交易完成后，这位首席执行官现在拥有该公司7,785,820股股票，价值约114,918,703.20美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可通过此超链接。此外，在11月14日星期一的一笔交易中，董事杰克·鲍尔出售了16,000股该股。这些股票的平均价格为14.69美元，总价值为235,040.00美元。交易完成后，董事现在直接拥有该公司3000股股份，价值约44,070美元。关于这次销售的披露可以找到这里。过去三个月，内部人士抛售了146,500股公司股票，价值1,824,960美元。公司内部人士持有该公司15.90%的股份。
Cytek Biosciences Company Profile
赛特克生物科学公司简介
(Get Rating)
(获取评级)
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis.
Cytek Biosciences，Inc.是一家细胞分析解决方案公司，提供细胞分析工具，促进生物医学研究和临床应用的科学进步。它提供极光和北极光系统，这是一种光谱流动细胞仪，通过利用来自多个激光的荧光信号来区分单个细胞上的荧光标记来提供细胞分析；以及极光细胞分选系统，它利用全光谱图谱技术进一步拓宽了细胞分析的潜在应用。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Cytek Biosciences (CTKB)
- Is Seagate Technology Signaling the End of its Normalization?
- eHealth Stock Rises from the Ashes. Time to Get In?
- Can Yext A.I. Search Platform Drive Growth in 2023?
- Cassava Sciences Stock Undervalued with Its $124 Price Target?
- Constellation Brands: Are Consumers Trading Down for Rail Drinks?
- 免费获取StockNews.com关于Cytek生物科学的研究报告(CTKB)
- 希捷科技是否在暗示其正常化的结束？
- EHealth股票从灰烬中崛起。是时候上车了吗？
- Yext AI搜索平台能否推动2023年的增长？
- 木薯科学公司的股票以124美元的目标价被低估了？
- 星座品牌：消费者正在降低购买铁路饮料的价格吗？
Want to see what other hedge funds are holding CTKB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cytek Biosciences, Inc. (NASDAQ:CTKB – Get Rating).
想看看还有哪些对冲基金持有CTKB吗？访问HoldingsChannel.com获取Cytek Biosciences，Inc.(纳斯达克代码：CTKB-GET Rating)的最新13F备案文件和内幕交易信息。
Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Cytek生物科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Cytek Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。